GSK3B and supranuclear palsy, progressive, 1: The TAUROS trial to evaluate another GSK3β inhibitors (tideglusib) showed that while the test drug reduced brain atrophy in PSP patients (Höglinger et al., 2014) it failed to demonstrate clinical efficacy in patients with mild to moderate PSP (Tolosa et al., 2014).